Biocare Medical, LLC is pleased to announce the availability of a comprehensive line of HPV probes for in situ hybridization. Each digoxigenin-labeled individual probe is designed to detect HPV DNA viral subtypes 6, 11, 16, 18, 31 or 51.

Almost 80 million Americans are infected with Human Papilloma Virus (HPV), with about 14 million becoming newly infected each year. HPV is considered to be the most common sexually transmitted infection. Although relatively rare, cervical cancer resulting from HPV infection with so-called “high risk” viral subtypes afflicts over 11,000 women every year in the United States. Low risk HPV subtypes are responsible for 360,000 annual cases of genital warts and a smaller number of recurrent respiratory papillomatosis cases.

“With the introduction of our line of HPV probes, Biocare Medical strives to improve the molecular diagnostic tools available to pathologists, as well as advance diagnostic confidence. This is especially critical in cases of discriminating HPV-positive vs. HPV-negative oropharyngeal squamous cell carcinoma, where a correct diagnosis reduces therapy-related morbidity,” says Dr. David Tacha, Chief Scientific Officer of Biocare Medical.

About Biocare Medical
Biocare Medical, LLC is an innovator in developing and supplying world class automated immunohistochemistry (IHC) instrumentation and the full range of reagents for IHC and ISH lab testing. Biocare Medical is the market leader in simultaneous Multiplex IHC and antibody development, which aids in the assessment of clinical cases and accelerates turnaround time. The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare Medical is headquartered and has manufacturing facilities in Concord, California, and has a global distribution network. For more information, please visit www.biocare.net.

Email Cart